Breakthrough Retinal Implant Debuts in Europe, Eyes U.S. Launch
Exciting news for individuals living with inherited retinal diseases (IRDs) and age-related macular degeneration (AMD) as a groundbreaking retinal implant, dubbed the 'Cochlear implant for blindness,' has officially launched commercially in Europe. This innovative technology, known as PRIMA, offers the potential to restore functional central vision, a significant step forward for those who have experienced severe vision loss. The device is also anticipated to launch in the U.S. in 2027, bringing renewed hope to many.
A New Era for Vision Restoration
The PRIMA system, developed by Science Corporation, has received CE mark approval under the European Union Medical Device Regulation, allowing its commercial availability across 30 European countries. The first commercial implantations are expected to occur in Germany in August 2026, with more patients to follow throughout the year. This marks a pivotal moment, as it's the first treatment shown to restore functional central vision for patients with geographic atrophy (GA) caused by age-related macular degeneration.
Geographic atrophy is an advanced form of dry AMD that progressively destroys photoreceptors in the macula, leading to irreversible central vision loss. This condition affects over five million people globally, severely impacting their ability to read, recognize faces, and discern fine details. Existing treatments for GA primarily focus on slowing disease progression, but do not restore lost vision.
How PRIMA Works: A Glimpse into the Technology
The PRIMA system is a sophisticated brain-computer interface (BCI) that consists of two main components: a tiny, wireless photovoltaic chip implanted beneath the retina and a pair of specialized glasses. The glasses are equipped with a camera, a projector, and near-infrared light. They capture images and project them onto the subretinal implant. The chip then converts this light into electrical signals, stimulating the remaining healthy retinal cells and sending visual information to the brain.
While the goal is not to achieve normal vision, the implant aims to provide